Table 2 Treatment-emergent adverse events reported in ≥2% of patients in any treatment group by dosing interval (safety population)
Dosing Interval | Eptinezumab 100 mg | Eptinezumab 300 mg | Placebo | ||||||
|---|---|---|---|---|---|---|---|---|---|
Total n = 356 | Dose 1 n = 356 | Dose 2 n = 348 | Total n = 350 | Dose 1 n = 350 | Dose 2 n = 344 | Total n = 366 | Dose 1 n = 366 | Dose 2 n = 356 | |
Any event, n (%) | 155 (43.5) | 106 (29.8) | 64 (18.4) | 182 (52.0) | 120 (34.3) | 99 (28.8) | 171 (46.7) | 120 (32.8) | 79 (22.2) |
Nasopharyngitis | 19 (5.3) | 12 (3.4) | 6 (1.7) | 33 (9.4) | 19 (5.4) | 7 (2.0) | 22 (6.0) | 11 (3.0) | 11 (3.1) |
URTI | 15 (4.2) | 5 (1.4) | 6 (1.7) | 19 (5.4) | 8 (2.3) | 9 (2.6) | 20 (5.5) | 13 (3.6) | 4 (1.1) |
Migraine | 6 (1.7) | 1 (0.3) | 4 (1.1) | 8 (2.3) | 2 (0.6) | 4 (1.2) | 16 (4.4) | 6 (1.6) | 7 (2.0) |
Nausea | 6 (1.7) | 4 (1.1) | 2 (0.6) | 12 (3.4) | 10 (2.9) | 4 (1.2) | 7 (1.9) | 4 (1.1) | 3 (0.8) |